Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project
Background:
Approximately 800,000 children die each year due to pneumococcal disease and >90% of these deaths occur in developing countries where few children have access to life-saving serotype-based vaccines. Understanding the serotype epidemiology of invasive pneumococcal disease (IPD) among children is necessary for vaccine development and introduction policies. The aim of this study was to systematically estimate the global and regional distributions of serotypes causing IPD in children <5 years of age.
Methods and Findings:
We systematically reviewed studies with IPD serotype data among children <5 years of age from the published literature and unpublished data provided by researchers. Studies conducted prior to pneumococcal conjugate vaccine (PCV) introduction, from 1980 to 2007, with ≥12 months of surveillance, and reporting ≥20 serotyped isolates were included. Serotype-specific proportions were pooled in a random effects meta-analysis and combined with PD incidence and mortality estimates to infer global and regional serotype-specific PD burden. Of 1,292, studies reviewed, 169 were included comprising 60,090 isolates from 70 countries. Globally and regionally, six to 11 serotypes accounted for ≥70% of IPD. Seven serotypes (1, 5, 6A, 6B, 14, 19F, 23F) were the most common globally; and based on year 2000 incidence and mortality estimates these seven serotypes accounted for >300,000 deaths in Africa and 200,000 deaths in Asia. Serotypes included in both the 10- and 13-valent PCVs accounted for 10 million cases and 600,000 deaths worldwide.
Conclusions:
A limited number of serotypes cause most IPD worldwide. The serotypes included in existing PCV formulations account for 49%–88% of deaths in Africa and Asia where PD morbidity and mortality are the highest, but few children have access to these life-saving vaccines.
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project. PLoS Med 7(10): e32767. doi:10.1371/journal.pmed.1000348
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1000348
Souhrn
Background:
Approximately 800,000 children die each year due to pneumococcal disease and >90% of these deaths occur in developing countries where few children have access to life-saving serotype-based vaccines. Understanding the serotype epidemiology of invasive pneumococcal disease (IPD) among children is necessary for vaccine development and introduction policies. The aim of this study was to systematically estimate the global and regional distributions of serotypes causing IPD in children <5 years of age.
Methods and Findings:
We systematically reviewed studies with IPD serotype data among children <5 years of age from the published literature and unpublished data provided by researchers. Studies conducted prior to pneumococcal conjugate vaccine (PCV) introduction, from 1980 to 2007, with ≥12 months of surveillance, and reporting ≥20 serotyped isolates were included. Serotype-specific proportions were pooled in a random effects meta-analysis and combined with PD incidence and mortality estimates to infer global and regional serotype-specific PD burden. Of 1,292, studies reviewed, 169 were included comprising 60,090 isolates from 70 countries. Globally and regionally, six to 11 serotypes accounted for ≥70% of IPD. Seven serotypes (1, 5, 6A, 6B, 14, 19F, 23F) were the most common globally; and based on year 2000 incidence and mortality estimates these seven serotypes accounted for >300,000 deaths in Africa and 200,000 deaths in Asia. Serotypes included in both the 10- and 13-valent PCVs accounted for 10 million cases and 600,000 deaths worldwide.
Conclusions:
A limited number of serotypes cause most IPD worldwide. The serotypes included in existing PCV formulations account for 49%–88% of deaths in Africa and Asia where PD morbidity and mortality are the highest, but few children have access to these life-saving vaccines.
: Please see later in the article for the Editors' Summary
Zdroje
1. World Health Organization 2008 The global burden of disease: 2004 update Geneva World Health Organization
2. O'BrienKL
WolfsonLJ
WattJP
HenkleE
Deloria-KnollM
2009 The global burden of disease due to Streptococcus pneumoniae in children less than 5 years of age. Lancet 374 893 902
3. HausdorffWP
BryantJ
ParadisoPR
SiberGR
2000 Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 30 100 121
4. CherianT
2007 WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26–27 October 2006, Geneva. Vaccine 25 6557 6564
5. World Health Organization 2009 Global literature review of Haemophilus influenzae type b and Streptococcus pneumoniae invasive disease among children less than five years of age 1980–2005 Geneva World Health Organization
6. DerSimonianR
LairdN
1986 Meta-analysis in clinical trials. Controlled Clinical Trials 7 177 188
7. United Nations Population Division World Population Prospects: The 2004 Revision Analytical Report. Available: http://www.un.org/esa/population/publications/WPP2004/WPP2004_Vol3_Final/Preface_TOC_ExpNotes.pdf. Accessed 19 October 2009
8. FleissJL
1986 The design and analysis of clinical experiments New York Wiley
9. EfronB
TibshiraniRJ
1993 An introduction to the bootstrap New York Chapman & Hall/CRC Press
10. WhitneyCG
FarleyMM
HadlerJ
HarrisonLH
BennettNM
2003 Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 1737 1746
11. WhitneyCG
PilishviliT
FarleyMM
SchaffnerW
CraigAS
2006 Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 1495 1502
12. EskolaJ
TakalaAK
KilpiTM
LankinenKS
KayhtyH
1998 Clinical evaluation of new pneumococcal vaccines: the Finnish approach. Dev Biol Stand 95 85 92
13. ParkIH
PritchardDG
CarteeR
BrandaoA
BrandileoneMC
2007 Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 45 1225 1233
14. ParkIH
ParkS
HollingsheadSK
NahmMH
2007 Genetic basis for the new pneumococcal serotype, 6C. Infect Immun 75 4482 4489
15. DaganR
2009 Serotype replacement in perspective. Vaccine 27 Suppl 3 C22 C24
16. ConstenlaDGE
Pio de la HozF
O'LoughlinR
SinhaA
ValenciaJE
2009 The burden of pneumococcal disease and cost-effectiveness of a pneumococcal vaccine in Latin America and the Caribbean: a review of the evidence and a preliminary economic analysis Washington (D.C.) Sabin Vaccine Institute
17. YaroS
LourdM
TraoréY
Njanpop-LafourcadeBM
SawadogoA
2006 Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso. Clin Infect Dis 43 693 700
18. FenollA
GranizoJJ
AguilarL
GiménezMJ
Aragoneses-FenollL
2009 Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 47 1012 1020
19. LagosR
MuñozA
San MartinO
MaldonadoA
HormazabalJC
2008 Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994–2007. J Infect Dis 198 1809 1817
20. KnollMD
MoisiJC
MuhibFB
WonodiCB
LeeEH
2009 Standardizing surveillance of pneumococcal disease. Clin Infect Dis 48 Suppl 2 S37 S48
21. LevineOS
CherianT
HajjehR
KnollMD
2009 Progress and future challenges in coordinated surveillance and detection of pneumococcal and Hib disease in developing countries. Clin Infect Dis 48 Suppl 2 S33 S36
22. RodenburgGD
de GreeffSC
JansenAG
de MelkerHE
SchoulsLM
2010 Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 16 816 823
23. ImöhlM
ReinertRR
van der LindenM
2010 Temporal variations among invasive pneumococcal disease serotypes in children and adults in Germany (1992–2008). Int J Microbiol 2010 874189
24. WintherTN
KristensenTD
KaltoftMS
KonradsenHB
KnudsenJD
2009 Invasive pneumococcal disease in Danish children, 1996–2007, prior to the introduction of heptavalent pneumococcal conjugate vaccine. Acta Paediatr 98 328 331
25. World Health Organization 2003 Pneumococcal vaccines. Wkly Epidemiol Rec 78 97 120
26. United Nations 2001 General Assembly, 56th session. Road map towards the implementation of the United Nations millennium declaration: report of the Secretary-General New York New York United Nations
27. PneumoADIP 2008 Pneumococcal Regional Serotype Distribution for Pneumococcal TPP. Available: http://www.vaccineamc.org/files/TPP_Codebook.pdf. Accessed 19 October 2009
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2010 Číslo 10
- Hydroresponzivní krytí v epitelizační fázi hojení rány
- Jak rozpoznat pacienty s familiární hypercholesterolémií ve své praxi
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
- Myasthenia gravis: kombinace chirurgie a farmakoterapie jako nejefektivnější modalita?
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
Najčítanejšie v tomto čísle
- Epigenetic Epidemiology of Common Complex Disease: Prospects for Prediction, Prevention, and Treatment
- Editors, Publishers, Impact Factors, and Reprint Income
- Systematic Evaluation of Serotypes Causing Invasive Pneumococcal Disease among Children Under Five: The Pneumococcal Global Serotype Project
- The Persisting Burden of Intracerebral Haemorrhage: Can Effective Treatments Be Found?